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PCRAbstract Hepatitis C virus (HCV) is a blood borne, circular and positive single stranded virus with
high spread rates. With the passage of time the frequency of HCV is increasing in different parts of
the world. HCV is a major cause, which may end in liver cirrhosis and hepatocellular carcinoma.
HCV has six main genotypes with many subtypes, which have variable sequence homology with
each other. Symptoms can appear anytime from 2 weeks to 6 months, which include jaundice, fati-
gue, gray-colored stool, joint pain, belly pain, weakness, anorexia, itchy skin and dark urine.
Genotyping is more signiﬁcant for planning of HCV treatment period and helps to cure HCV infec-
tions. For the quantiﬁcation and identiﬁcation of hepatitis C virus-ribonucleic acid, many molecu-
lar techniques are performed; the most signiﬁcant are HCV ELISA, quantitative HCV-RNA PCR
and recombinant immunoblot assay. PCR is the major technique targeting 50 untranslated region
(UTR). HCV can be transmitted by contaminated blood, ear and nose piercing and contaminated
medical instruments. To overcome the rate of HCV, guidance should be provided to make aware
the persons about risk factors, transmission and prevention. Discovery and designing of new ther-
apies and vaccines to overcome this disease are the necessity of the present era. Four types of vac-
cines such as vector vaccines, peptide vaccines, DNA vaccines and recombinant protein vaccines are
available in clinical trials.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Hepatitis C virus (HCV) is an infectious pathogen causing
great damage to the liver [1]. HCV was initially isolated from
the serum of an individual with non-A, non-B hepatitis discov-
ered by Choo et al. in 1989 [2]. Brieﬂy after cloning of HCV,
the newly discovered virus was found to be the main reason
of about 90% of non-A, non-B hepatitis in the US [3]. It is
the most common cause of chronic liver disease ending in liver
cirrhosis and hepatocellular carcinoma [4]. Globally, it is the
main cause of death and morbidity [5] with major global health
issues affecting 180 million individuals of the world and 10 mil-
lion people in Pakistan [6]. Every year about 3–4 million indi-
viduals are affected by HCV [7]. About 27% individuals are
infected and have cirrhosis and 25% have hepatocellular carci-
noma [8].
HCV is enveloped, small circular, positive-sense and single
stranded ribonucleic acid (RNA) virus from genus
Hepacivirus, family Flaviviridae with a diameter of 50 nm [9].Figure 1 Proteins encoded by HCV genome. All theThe total length of RNA genome is about 9.6 kb with one
open reading frame (ORF) and 50 and 30 untranslated regions
(UTRs) at both edges [10]. 50UTR is a more conserved part of
HCV genome, which helped in evolutionary studies and geno-
typing [11,12].
The open reading frame encodes a polyprotein, which is
comprised of 10 viral proteins named as Core (C), E1, E2,
P7, NS2, NS3, NS4A, NS4B, NS5A and NS5B (Fig. 1). The
3 structural proteins are C, E1 and E2, while the 7 nonstruc-
tural proteins are P7, NS2, NS3, NS4A, NS4B, NS5A and
NS5B [13]. Among structural proteins, core protein (21 kDa)
consists of 191 amino acids, which are important components
of nucleocapsid. Core protein modulates gene transcription,
cell death, cell proliferation and interference metabolism lead-
ing to oxidative stress, liver steatosis and ﬁnally hepato cellular
carcinoma (HCC). HCV envelope proteins E1 and E2 are gen-
erally glycosylated and have played a major role in cell entry.
Protein P7 is responsible for ion channel and virus assembly
[14]. The proteins NS3 serine protease and NS5B played astructural and nonstructural proteins are shown.
Table 1 Different transmission routes of HCV identiﬁed in
different studies.
Transmission routes Percentage
Dental treatment 1.6
IVDU 60
Blood transfusion 10
Tattoo 46.3
Ear piercing 30.1
Needle stick 2
Sexual transmission 15
Nail trimming 24.3
Shaving 14.5
Surgical treatments 7.6
Hepatitis C virus genotypes 293major role in viral replication. Main targets for antiviral drug
development are structural proteins, NS5B RNA-dependent
RNA polymerase and NS3 serine protease [15].
HCV has six main genotypes (1–6) with multiple subtypes.
The most worldwide epidemic genotypes are 1–3. Genotyping
is most signiﬁcant for planning of HCV treatment and helps to
cure HCV infections [16]. Due to the high prevalence and
increasing rate of HCV infected persons day by day, the aim
of the present review was to collect information about HCV
virus, its symptoms and cure by awareness on utilization of
sterilized instruments/syringes in health care centers, preparing
antiviral drugs, introducing new therapies and vaccines for
HCV control.2. Frequency of HCV genotypes and infections
HCV-1, HCV-2 and HCV-3 are distributed worldwide,
whereas HCV-4, HCV-5 and HCV-6 are present in certain
areas of the globe. The frequency of HCV is highest in few
countries and areas, such as in Europe 25 million cases are
HCV positive [17]. In Pakistan, HCV is 5% prevalent [18],
whereas 5–9% prevalence is detected in Khyber Pakhtunkhwa
province of Pakistan [19] causing liver cancer [20]. HCV-4 is
prevalent among Middle East and Africa causing more than
80% of HCV infections and has recently spread to several
European countries. Egypt has the highest prevalence of HCV
worldwide (15%) and the highest frequency of HCV-4 responsi-
ble for almost 90% of infections and a major cause of chronic
hepatitis, liver cirrhosis, hepatocellular carcinoma and trans-
plantation in the country. Although HCV-4 is the cause of about
20% of the 170 million cases of hepatitis C in the world [21]. In
the United States, the number of new cases of HCV infection has
declined from a peak of 200,000 annually to about 17,000 in
2007. Up to 85% of newly infected people failed to eliminate
the virus and become chronically infected. HCV infection is
the leading cause of liver transplantation in the US and is a risk
factor for liver cancer [22].3. Acute infection and chronic infection
Acute hepatitis C infection is infrequently diagnosed as the
majority of acutely infected individuals are asymptomatic. In
the transfusion setting, acute HCV infection has been known
to be 70–80% asymptomatic and 20–30% of adults showed
clinical symptoms [23,24]. Chronic hepatitis C is marked by
the persistence of HCV-RNA in the blood for at least
6 months after onset of acute infection. HCV is self-limiting
in only 15–25% of patients, whom HCV-RNA in the serum
becomes undetectable and ALT levels returned to normal.
Approximately 75–85% of infected patients do not clear the
virus by 6 months and chronic hepatitis developed in them.
The rate of chronic HCV infection is affected by many factors,
including the age at time of infection, gender, ethnicity and
development of jaundice during acute infection [25].
4. Route of transmission and symptoms of HCV
HCV can be transmitted through intravenous drug use
(IVDU), blood to blood contact, birth to an infected mother,
blood products, organ transplantation, use of unsterilizedinjection needles, use of unsterilized instruments for nose and
ear piercing or tattoos (Table 1) and these reasons are the
major sources of transmission of HCV in Pakistan [26,27]. In
developing countries HCV is transmitted by IVDU, sexual
exposure and blood products [26,28]. Virus cannot be trans-
mitted from one person to other by sharing drink or food with
an infected individual [29].
Symptoms can appear anytime from 2 weeks to 6 months
after a person is infected with the virus. Symptoms include
jaundice, fatigue, gray-colored stool, joint pain, belly pain,
weakness, anorexia, itchy skin and dark urine. Mild cognitive
problems and fatigue are the major symptoms of chronic hep-
atitis C [25]. A study conducted in Egypt showed the symp-
toms of HCV including history of fatigue, diarrhea and
abdominal pains. Another study performed on 77 Spanish
and Italian children revealed that HCV was generally asymp-
tomatic among them [30].
5. Diagnosis and genotyping of HCV
For the quantiﬁcation and detection of HCV-RNA, many
molecular biology techniques are described (Table 2). The sig-
niﬁcant technique is PCR targeting 50UTR region [31]. Several
tests are used to diagnose the hepatitis C virus, which include
HCV antibody enzyme immunoassay (ELISA), quantitative
HCV-RNA PCR and recombinant immunoblot assay [32].
HCV-RNA by PCR is the quickest and most informative
method for HCV detection, while long infection time is
required to detect virus using antibodies [33]. The hepatitis C
diagnosis mostly depends on serological assay and HCV-
RNA. For the epidemiology surveillance and screening,
conﬁrmatory recombinant immunoblot assay and ELISA are
performed for the identiﬁcation of HCV-speciﬁc antibodies
(anti-ssHCV). For the identiﬁcation of viral genome and
conﬁrmation of active infection, qualitative polymerase
chain reaction is used. This methodology is quite effective in
monitoring disease activity and treatment response [34].
6. Bioinformatics analysis and databases for HCV
A study conducted in Saudi Arabia on HCV positive samples
by sequencing their 50UTR regions revealed the identiﬁcation
of new HCV isolates. For sequencing and ampliﬁcation, speci-
ﬁc primers were used which target the 50UTR region. In this
study most of the HCV isolates were G4 (76.4%) and small
Table 2 Different diagnostic techniques for HCV detection [35,36]. TMA: transcription mediated ampliﬁcation, bDNA: branched
DNA, RT-PCR: reverse transcription-PCR, qPCR: quantitative PCR.
Assay Procedures Lower limit of detection
(dynamic range) IU/mL
Versant HCV-RNA TMA (manual) 10
Cobas TaqMan HCV test Real-time PCR (semi automated) 15 (43–69,000,000)
Amplicor HCV v2.0 RT-PCR (manual) 50
Abbott real-time Real-time PCR (semi automated) 30 (12–100,000,000)
Amplicor HCV monitor RT-PCR (manual) 50 (600–700,000)
Super Quant Competitive reverse transcriptase PCR (semi automated) 30–1,470,000
Versant HCV-RNA 3.0 bDNA (semi automated) 18 (43–69,000,000)
Amplicor HCV monitor v2.0 RT-PCR (manual) 600 (600–500,000)
Cobas Ampliprep and TaqMan qPCR (semi automated) 18 (43–69,000,000)
Table 4 Treatments of HCV by pegylated interferon + rib-
avirin. LD RBV: lower dose of ribavirin, SD RBV: standard
dose of ribavirin.
294 F. Nouroz et al.numbers were G1 (19.6%). Los Alamos HCV database was
used for comparing the received HCV sequence with HCV ref-
erence sequences taking whole genome for phylogenetic analy-
sis. Highly similar sequences (98–100%) were selected, where
majority of the isolates showed homology with G4 reference
sequence. Few isolates were identical with different subtypes
(G4, G1 and G6). Phylogenetic analysis represented the simi-
larity of most isolates, which were identical to the Egyptian,
East and North American isolates. Multiple sequence align-
ment analysis and sequence WebLogos represented 92–
95.5% nucleotide conservation of HCV isolates with G4 and
G1. All the resulting sequences were submitted to the
GenBank database of NCBI [37].
7. Prevalence of HCV genotypes
HCV prevalence is variable in various regions of the world and
among different groups of a community [38]. Genotype 1a is
most prevalent in the United States and Northern Europe
(Table 1), while 1b is the most common genotype worldwide
[39]. In Europe and Japan, genotype 2a and 2b are most preva-
lent, while 2c subtype is most frequent in Northern Italy. In
Africa and Middle East, the most prevalent genotype is 4
(Table 3). Genotype 5 and 6 are most common in South
Africa and Asia [40,41]. Genotype 3a is most common in
Pakistan in comparison to 3b and 1a [42]. In the nucleotide
composition of genome, the six main genotypes are about
30–35% different from one another, while approximately 20–
25% subtypes are different from each other [39].
Genotype 1 is more common in the world including 83.4
million cases (42.6% of total HCV cases), of which about
1/3 are present in East Asia. After genotype 1, genotype 3 is
more common worldwide including 54.3 million cases (30.1%Table 3 Worldwide prevalence of HCV genotypes.
Countries Prevalent
genotypes
Refs.
Northern Europe and United States G1a [10]
America, Europe, Japan and Italy G2a, G2b, G2c [40,41]
India, Nepal and Pakistan G3, G3a [42]
Africa and Middle East G4 [40,41]
South Africa G5 [43]
Hong Kong and Southeast Asia G6 [43]of HCV cases). G-2, G-4 and G-6 are responsible for a total
22.8% of whole cases, while G-5 includes the remaining percent-
age (>1%). In most countries G-1 and G-3 are most prevalent
in comparison to other genotypes while G-4 and G-5 are preva-
lent in less developed countries [44]. Hospital based studies of
various Pakistani cities revealed that the prevalence rate of
HCV is 5.31% (Islamabad), 2.45% (Rawalpindi), 4.0%
(Multan), 20.89% (Mardan), 5% (Faisalabad), 4–6% (Buner)
and 25.7% (Northern areas) [34,45]. A similar study conducted
in Bangladesh revealed that G-3 was the most prevalent geno-
type in comparison to other genotypes [16].
A study conducted on HCV-RNA positive patients in
Isfahan province (Iran) revealed that the common rate of
HCV genotypes was 3a (61.2%), 1a (29.5%), 1b (5.1%), geno-
type 2 (2%) and mixed types 1a + 3a (2%) [46]. In other stud-
ies type 3 cases are completely represented by subtype 3a, while
type 4 cases (52.3%) are represented by subtype 4c and 4d in
Italy [47]. Several other studies conﬁrmed the high prevalence
of genotype 1a and 1b in HCV patients from different parts of
the world [48–50].
8. HCV treatment by different therapies, vaccines and local
remedies
General treatment is recommended for HCV patients with
complications in the liver (Table 4). For the treatment of
chronic hepatitis C, the combination of pegylated interferonHCV
Genotypes
Treatment
regimen
Time
(weeks)
SVR (%) Citation
HCV-1 PegIFN+ SD RBV 48 44 [57]
PegIFN+ SD RBV 24 94 [58]
PegINF alpha-2b 48 42 [59]
HCV-2/3 Ribavirin 48 76 [60]
PegINF+ LD RBV 24 75 [57]
PegIFN+ SD RBV 16 100 [57]
HCV-4 PegINF alpha-2b 24 29 [61]
PegIFN+ SD RBV 48 68 [62]
HCV-6 PegIFN+ SD RBV 48 86 [63]
Hepatitis C virus genotypes 295alpha-2a or 2b and ribavirin may be used. The endpoint of
HCV treatment is sustained virological response (SVR),
deﬁned by an undetectable HCV-RNA in serum with a sensi-
tive assay (lower limit of detection of 10–50 IU/mL) 24 weeks
after the end of treatment. Genotype 2 and 3 infected patients
require 24 weeks of treatment and a low dose of ribavirin
(800 mg daily). In contrast, genotype 1, 4, 5 and 6 infected
individuals requires 48 weeks of treatment and a body weight
based dose of ribavirin (1000–1400 mg daily) [35]. A combina-
tion of treatment is administered for a period of 24–48 weeks
depending on the HCV genotype (Table 4). This treatment
includes ribavirin and pegylated interferon alpha in combina-
tion [32]. Around 70% and 80% cure rates were achieved for
genotype 2 and 3 respectively and 45–70% for other genotypes
[51]. Recently two latest therapeutic agents called as boceprevir
and telaprevir are introduced in few countries, which are pro-
tease inhibitors and control HCV [52]. The combination of
telaprevir or boceprevir with pegylated interferon-alpha and
ribavirin is highly beneﬁcial in controlling genotype 1 [53].
The treatment of HCV is more effective during the ﬁrst six
months than once it becomes chronic. If new infection devel-
ops in a person and remained uncontrolled till 8–12 weeks,
pegylated interferon is strongly recommended for a period of
24 weeks to control the virus [33]. HCV genotype 1, 4, 5 or 6
and their associated diseases are controlled by administrating
a combination of Sofosbuvir with ribavirin and interferon,
which was found to be 90% effective against the viral diseases
[54]. In Japan during December 2013, pegylated-interferon,
simeprevir (SMV) and ribavirin (RBV) triple combination
therapy was used to treat this disease specially genotype 1 in
clinical practice [55]. In the patients of genotype 1 (42–46%),
G-2 and G-3 (76–82%), a signiﬁcantly increased response
was detected for polyethylenglycol (PEG)-conjugated inter-
feron alpha in comparison to the conventional interferon alpha
[56] (Table 4).
Several alternative treatments or traditional remedies are
used by infected people to control HCV. These include the
use of Quranic verses (Dam) and other alternative and home-
opathic medicines to cure it due to high costs of conventional
medicines. Around 50% individuals follow alternative medici-
nes and 65% are using both conventional and unconventional
medicines [64]. Some infected patients try herbal medicine to
recover from virus such as Proanthocyandin obtained from
leaves of blue berry, Rhodiolakirilowii (Regel), Maxim and
laccase obtained from oyster mushroom but no affective
reports are documented [65].Table 5 Recombinant protein, peptide and vector vaccines to cont
Vaccine type Structure Phase Individ
Recombinant
protein vaccine
HCV core protein I, IIa 30 heal
Peptide vaccine Peptide received from core protein
(C35-C44)
I 26 infe
HCV (
cure ab
Vector vaccines Adenovirus vector (Ad6 and Adch3)
showing NS3 and NS5B proteins
I 36 heal
DNA vaccines ChonVac-C plasmid NS3 and 4A
plus electroporation
I, IIa 12 G-1
individ9. Management of HCV in Pakistan
Pakistan is a developing country with less medical facilities avail-
able for its citizens. Around 75% Pakistanis are living below
poverty line and cannot afford expensive medicines and drugs.
More than 80 different interferon’s brands are available in
Pakistan, but they are out of reach of common people due to
their high costs. The ‘‘Prime Minister Program for prevention
and control of hepatitis’’ was launched in recent years and dur-
ing 2006–2008, around 20,000 patients received free interferon
treatment but the treated cases were only 0.01% of the total
cases. After 12 years of this program, still 3/4 patients are away
to receive this treatment. For Pakistani patients, currently a
combination of ribavirin and interferon alpha is recommended,
which showed high viral control response [34,42].
A higher sustained virological response (SVR) rate was sig-
niﬁcantly detected in Pashtoons (69.2%) in comparison to
Punjabi (45.5%), Sindhi (45.5%) and Balouchi (50%) tribes
after administering INF-alpha plus ribavirin to patients. The
highest SVR in patients with HCV was genotype 2 (69.7%),
followed by G-3 (57.3%), while the lowest SVR was investi-
gated in G-1 infection (24.3%) [42]. Another study comprising
190 patients from both sexes between age limits 20–68 years
revealed that G-3 (48.9%) was the most prevalent genotype
in comparison to G-1 (42.6%). Of the overall infected persons,
the response rate was 49.6%, 68.8% and 62.4% in G-1, G-2
and G-3 respectively [66].
10. Vaccines used for HCV control
Four types of vaccines (Table 5) are available in clinical trials
naming vector vaccines, peptide vaccines, recombinant protein
vaccines and DNA vaccines [67]. These vaccines are formed to
induce targeting envelope part of the pathogen, T-cell
responses and targeting nonstructural proteins [68].
Conserved HCV core protein vaccine is used with adjuvant
made up of cholesterol, saponin and phospholipid and is
known as ISCOMATRIX. The vaccine is well tolerated and
showed a well developed humoral response [69]. According
to a Japanese study, a peptide obtained from HCV core section
(C35–C44) was used in Phase I. Of the 26 infected persons, 3
responded to standard therapy and 23 were non responders
to ribavirin and pegylated-interferon [70]. Adenovirus vectors
are Phase I vaccines. The two adenoviral vectors are Ad6
and Adch3, displaying NS3 and NS5B proteins (Table 5) [71].rol HCV and its diseases.
uals Outcome Citation
thy individuals Good tolerated and well
developed antibody
response
[69]
cted person with chronic
23 non responder and three
le)
Good tolerated and few
showed response
[70]
thy individuals Greatly immunogenic and
good tolerated
[71]
infected treated native
uals
Good tolerated, of 6 only 4
patients are receiving high
doses
[72]
296 F. Nouroz et al.11. Side effects of IFN therapy and ribavirin
In the starting week of IFN treatment, ﬂu like symptoms can
occur. Further side effects may be arthralgia, chill, headaches,
fever and myalgia. Negative effects of neuropsychiatric include
severe fatigue, irritability and severe depression, which may
lead to suicide attempts [73]. A major side effect of ribavirin
is hemolytic anemia [59].
12. Prevention and management of HCV diseases
Although few patients are cured at initial stages but the acti-
vated virus after some time will be uncontrollable and can
cause human deaths. No proper vaccine and antiviral drugs
are available to control 100% HCV. Our initial focus should
be on prevention including safe injection practices in hospitals
and another places, safe blood supply and guidance to the
injection drug abuser or intravenous drug users about the risk
of HCV. Health education is necessary to minimize the rate of
HCV. Special programs should be launched to make aware the
public on risk factors, transmission and prevention of the dis-
ease. Safe blood test and other laboratory tests are necessary
for an early diagnosis of HCV [74].
13. Conclusion
HCV is a major global health issue affecting several individu-
als around the globe. The prevalence of HCV genotypes varies
all over the world due to virus mutation, route of infection and
population analysis. Monthly or yearly blood tests should be
necessary for the diagnosis of HCV. In a majority of people,
HCV causing liver cirrhosis and hepatocellular carcinoma can-
not be diagnosed at early stages. New therapies with fewer or
no side effects should be introduced to cure the virus.
Guidance plays an important role in preventing people from
this infection. Awareness seminars regarding the risk factor
of HCV infection should be regularly arranged and discovery
of new vaccines by scientists is of utmost importance to over-
come this disease.
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